BEYOND KRAS: Other markers and potential treatment strategies for KRAS mutant and wild-type patients

Current Treatment Options in Oncology

Volumn 12, Issue 2, 2011, Pages 126-135

  Cercek, Andrea ^a   Saltz, Leonard ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; BEVACIZUMAB; CETUXIMAB; CIXUTUMUMAB; CONATUMUMAB; DALOTUZUMAB; FLUOROURACIL; FOLINIC ACID; GANITUMAB; IRINOTECAN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; MUTANT PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN PIK3CA; RILOTUMUMAB; SORAFENIB; STA 9090; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; VISMODEGIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EXON; GENE MUTATION; HUMAN; MEDICAL DECISION MAKING; MELANOMA; MUTATIONAL ANALYSIS; NONHUMAN; PROGNOSIS; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; WILD TYPE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HEDGEHOG PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MAP KINASE KINASE KINASES; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECEPTORS, DEATH DOMAIN; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79958050915     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0147-3     Document Type: Article

References (35)

1. J Baselga J Albanell 2002 Epithelial growth factor receptor interacting agents Hematol Oncol Clin North Am 16 1041 1063 12512382 10.1016/S0889-8588(02) 00055-2 (Pubitemid 35462913)
2. J Baselga 2002 Why the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 7 Suppl 4 2 8 12202782 10.1634/theoncologist.7- suppl-4-2 1:CAS:528:DC%2BD38XnsFOiurw%3D (Pubitemid 34977157)
3. DS Salomon R Brandt F Ciardiello, et al. 1995 Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 183 232 7612182 10.1016/1040-8428(94)00144-I 1:STN:280: DyaK2Mzjs1KgsQ%3D%3D
4. Saltz LB RM, Hochester H: Cetuximab plus irinotecan is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor (abstract). J Clin Oncol. 20, 2001
5. Saltz LB MN, Loeher PJ, et al: Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor (abstract). J Clin Oncol 21, 2002
6. D Cunningham Y Humblet S Siena, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 15269313 10.1056/NEJMoa033025 1:CAS:528: DC%2BD2cXlvFGitbk%3D (Pubitemid 38944402)
7. ER Camp J Summy TW Bauer, et al. 2005 Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor Clin Cancer Res 11 397 405 15671571 1:CAS:528:DC%2BD2MXhtVegtbw%3D (Pubitemid 40075820)
8. Hecht JR PA, Malik I, et al: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis (abstract). J Clin Oncol 22, 2004
9. Berlin J NM, Swanson P, et al: Panitumumab antitumor activity in patients with metastatic colorectal cancer (mCRC expressing >10% epidermal growth factor receptor (EGFr) (abstract).. J Clin Oncol 24, 2006
10. E Van Cutsem M Peeters S Siena, et al. 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 13 1658 1664 17470858 10.1200/JCO.2006.08.1620 (Pubitemid 46797944)
11. S Khambata-Ford CR Garrett NJ Meropol, et al. 2007 Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 3230 3237 17664471 10.1200/JCO.2006.10.5437 1:CAS:528:DC%2BD2sXhtVWqs7rF (Pubitemid 47325606)
12. A Lievre JB Bachet V Boige, et al. 2008 KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 374 379 18202412 10.1200/JCO.2007.12.5906 1:CAS:528:DC%2BD1cXitVGntLc%3D (Pubitemid 351171687)
13. RG Amado M Wolf M Peeters, et al. 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626 1634 18316791 10.1200/JCO.2007.14.7116 1:CAS:528:DC%2BD1cXltlWhsrw%3D The study demonstarted the resistance to anti-EGFR therapy in KRAS mutated mcrc.
14. Van Cutsem E LI, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, et al: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or wihtout cetuximab: The CRYSTAL experience. J Clin Oncol. 26, 2008.
15. C Bokemeyer I Bondarenko A Makhson, et al. 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663 671 19114683 10.1200/JCO.2008.20.8397 1:CAS:528:DC%2BD1MXjsVCjsrk%3D
16. Punt CJTJ, Rodenburg CJ, Cats A, Creemers G, Schrama JG, Erdkamp FL, et al: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colrectal cancer (ACC), the CAIRO2 study if the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol. 26, 2008
17. W De Roock DJ Jonker F Di Nicolantonio A Sartore-Bianchi 2010 Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab JAMA. 304 16 1812 1820 20978259 10.1001/jama.2010.1535
18. F Di Nicolantonio M Martini F Molinari, et al. 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705 5712 19001320 10.1200/JCO.2008.18.0786 the study showed resistance to anti-EGFR therapy in BRAF mutated mcrc
19. F Loupakis A Ruzzo C Cremolini, et al. 2009 KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 101 715 721 19603018 10.1038/sj.bjc.6605177 1:CAS:528:DC%2BD1MXpvFyisb0%3D
20. F Cappuzzo M Varella-Garcia 2008 Finocchiaro., Skokan M., Gajapathy S., Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients British Journal of cancer 99 83 89 18577988 10.1038/sj.bjc.6604439 1:CAS:528:DC%2BD1cXnvFeru7Y%3D (Pubitemid 351920237)
21. A Ruzzo C Cremolini F Loupakis D Fornaro B Santini 2009 Association of BRAF mutations and EGFR Intron-1 L/L genotype with ersistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695 suppl; abstr 4058
22. Lambrechts W, De Roock H, Prenen J, De Schutter B, Jacobs B, Biesmans B, et al: The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 27, No 15 S (May 20 Supplement), 2009: 4020
23. W De Roock B Claes D Bernasconi J De Schutter B Biesmans, et al. 2010 Effects of KRAS, BRAF, NRAS and PIK3CA mutationson the efficacy of cetuximab plus chemotherapy in chemotehrapy-refractory metastatic colorectal cancer: a retropsective consortium analysis Lancet Oncol 11 8 753 762 20619739 10.1016/S1470-2045(10)70130-3
24. C Bokemeyer C Kohne P Rougier C Stroh M Schlichting 2010 Cetuximab with chemotehrapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status J Clin Oncol 28 7s 10.1200/JCO.2009.25.9937 This study is the first to demonstrate efficacy of dual targeted therapy in mcrc.
25. http://www.nelm-web.lbi.co.uk/en/NeLM-Area/News/2009 - -July/01/Phase-III-study-of-sunitinib-Sutent-in-metastatic-colorectal-cancer- discontinued/
26. Kopetz S, Desai J, Chan E, Hecht R, O'Dweyer, Lee RJ, et al: PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. Abstract 3534 JCO vol 28, No 15 suppl 2010; 3534.
27. A Sartore-Bianchi M Martini F Molinari, et al. 2009 PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Res 69 1851 1857 19223544 10.1158/0008-5472.CAN-08- 2466 1:CAS:528:DC%2BD1MXisFSrt7Y%3D
28. J Rinehart AA Adjei PM Lorusso, et al. 2004 Multicenter phase II study of the oral MEK inhibitor, CL-1040, in patients with advanced non-small cell lung cancer, breast, colon and pancreatic cancer J Clin Oncol 22 4456 4462 15483017 10.1200/JCO.2004.01.185 1:CAS:528:DC%2BD2cXhtFWqt77L (Pubitemid 41185111)
29. YP Hu SB Patil M Panasiewicz, et al. 2008 Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type-1 insulin-like growth factor receptor and epidermal growth factor receptor Cancer Res 68 8004 8013 18829558 10.1158/0008-5472.CAN-08-0280 1:CAS:528: DC%2BD1cXhtF2msLrI
30. DL Reidy E Vakiani MG Fakih LB Saltz 2010 Rnadomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with ot without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer J Clin Oncol. 28 27 4240 4246 20713879 10.1200/JCO.2010.30. 4154 1:CAS:528:DC%2BC3cXhsVSksr7I
31. VanCutsem E, Eng C, Tabernero J, Nowara E, et al: A Randomized Phase I/II Trial of AMG 102 or AMG 479 in combination with panitumumab (pmab) compared with pmab alone in patients with wild type KRAS metastatic colorectal cancer: Safety and efficacy results. J Clin Oncol 29: 2011 (suppl 4; abstr 366).
32. LB Saltz LS Rosen JL Marshall, et al. 2007 Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy J Clin Oncol 25 4793 4799 17947727 10.1200/JCO.2007.12.8637 1:CAS:528: DC%2BD2sXhtlCgsLbI (Pubitemid 350086483)
33. Berlin J. A phase 2, randomized, double-blind, placebo-controlled study of hedgehog pathway inhibitor (HPI) GDC-0449 in patients with previously untreated metastatic colorectal cancer (mCRC), abstract ESMO 2010 https://www.webges.com/cslide/library/esmo/mylibrary/search/session/0/509
34. S Kelly A Ashkenazi 2004 Targeting death receptors in cancer with Apo2L/TRAIL Curr Opin Pharmacol 4 333 339 10.1016/j.coph.2004.02.006 (Pubitemid 38987058)
35. L Saltz J Infante L Schwartzberg J Stephenson C Rocha-Lima F Galimi, et al. 2009 Fuchs Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC) J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695 suppl; abstr 4079